Company: PTHS
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001753926-25-001326
Chunk: 145

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 8
Chunk 145
---

    Net cash used in operating
    activities
     
    $
    (1,079,271
    )
     
    $
    (4,944,308
    )
     
    $
    (3,865,037
    )

    (78
    )%

    Net cash provided by financing activities

    625,000

    7,253,015

    (6,628,015
    )

    (91
    )%

    Net change in cash
     
    $
    (454,271
    ) 
     
    $
    2,308,707

    $
    (2,762,978
    ) 

    (120
    )%

42 

Net
Cash Used in Operating Activities

For
the six months ended June 30, 2025, we incurred a net loss of $5,416,550, and net cash flows used in operating activities was
$1,079,271. The cash flow used in operating activities was primarily due to a net loss of $5,416,550, offset by stock-based compensation
expense of $899,317, amortization of debt discount of $258,891, a change in account payable and accrued expense of $3,102,476,
a change in prepaid expenses of $52,959 and by a change in accrued compensation of $23,636.

For
the six months ended June 30, 2024, we incurred a net loss of $4,333,949, and net cash flows used in operating activities was
$4,944,308. The cash flow used in operating activities was primarily due to a net loss of $4,333,949, offset by stock-based compensation
expense of $751,530, amortization of debt discount of $605,630, a change in account payable and accrued expense of $1,481,113,
change in prepaid expenses of $158,102, an increase in accrued compensation in the amount of $282,518, and an increase in due
from Chromocell Corporation of $45,786.

Net
Cash (Used in) Provided by Investing Activities

The
Company neither received nor used cash in investing activities during the six months ended June 30, 2025 and 2024.

Net
Cash Provided by Financing Activities

For
the six months ended June 30, 2025, net cash flows provided by financing activities were $625,000